These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16499130)

  • 1. New approaches to preventing xerostomia.
    J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing radiation induced xerostomia.
    Koukourakis MI; Danielidis V
    Cancer Treat Rev; 2005 Nov; 31(7):546-54. PubMed ID: 16257125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of salivary hypofunction during and after radiotherapy.
    Shiboski CH; Hodgson TA; Ship JA; Schiødt M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology and management of radiation-induced xerostomia.
    Berk LB; Shivnani AT; Small W
    J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of xerostomia related to radiotherapy for head and neck cancer.
    Kahn ST; Johnstone PA
    Oncology (Williston Park); 2005 Dec; 19(14):1827-32; discussion 1832-4, 1837-9. PubMed ID: 16506635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial saliva products and drugs to treat xerostomia.
    Wynn RL; Meiller TF
    Gen Dent; 2000; 48(6):630-6. PubMed ID: 12004654
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future therapy strategies for salivary gland impairment].
    Aframian DJ; Palmon A; Nahlieli O
    Refuat Hapeh Vehashinayim (1993); 2004 Jul; 21(3):43-50, 93. PubMed ID: 15503981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy-induced salivary dysfunction.
    Ship JA; Hu K
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status of prevention and management of radiation-induced xerostomia].
    Ma DY; Qiu WL; Zhang CP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiation-induced xerostomia: how dry is your patient?
    Bruce SD
    Clin J Oncol Nurs; 2004 Feb; 8(1):61-7. PubMed ID: 14983765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
    Messerschmidt GL; Oleka N
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic pilocarpine for treatment of xerostomia.
    Berk L
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1333-40. PubMed ID: 18798702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilocarpine in the prevention of postirradiation xerostomia.
    Lajtman Z; Krajina Z; Krpan D; Vincelj J; Borcić V; Popović-Kovacić J
    Acta Med Croatica; 2000; 54(2):65-7. PubMed ID: 11028111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of saliva in oral health: strategies for prevention and management of xerostomia.
    Brosky ME
    J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
    Samuels MA
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
    [No Abstract]   [Full Text] [Related]  

  • 18. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
    Taylor SE; Miller EG
    Proc Soc Exp Biol Med; 1999 May; 221(1):14-26. PubMed ID: 10320627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.